DanCann Pharma A/S (NGM:DANCAN)

Market Cap	6.75M
Revenue (ttm)	10.06M
Net Income (ttm)	-11.50M
Shares Out	3.99M
EPS (ttm)	-2.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,225
Average Volume	18,931
Open	1.110
Previous Close	1.110
Day's Range	1.040 - 1.110
52-Week Range	1.000 - 60.000
Beta	2.06
RSI	43.07
Earnings Date	Aug 25, 2025

About DanCann Pharma

DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros. It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros...

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 5
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: DANCAN

Financial Performance

In 2024, DanCann Pharma's revenue was 7.37 million, an increase of 3.06% compared to the previous year's 7.15 million. Losses were -8.35 million, -86.59% less than in 2023.

Financial numbers in DKK